Table 2.
Timing of reported fatalities for selected seroprevalence studies
| Location | Cumulative fatalities | Change (%) | |||
|---|---|---|---|---|---|
| Study midpoint | 4 weeks later | 5 weeks later | Weeks 0–4 | Weeks 4–5 | |
| Europe | |||||
| Belgium | 6262 | 8843 | 9150 | 41 | 3 |
| Geneva, Switzerland | 255 | 287 | 291 | 13 | 1 |
| Spain | 26,834 | 27,136 | 28,324 | 1 | 4 |
| Sweden | 2586 | 3831 | 3940 | 48 | 3 |
| USA | |||||
| Connecticut | 2257 | 3637 | 3686 | 61 | 1 |
| Indiana | 932 | 1984 | 2142 | 113 | 8 |
| Louisiana | 477 | 2012 | 2286 | 322 | 14 |
| Miami | 513 | 1160 | 1290 | 126 | 11 |
| Minneapolis | 393 | 964 | 1093 | 145 | 13 |
| Missouri | 218 | 562 | 661 | 158 | 18 |
| New York | 20,212 | 28,663 | 29,438 | 42 | 3 |
| Philadelphia | 456 | 1509 | 1754 | 231 | 16 |
| San Francisco | 265 | 424 | 449 | 60 | 6 |
| Seattle | 536 | 732 | 775 | 37 | 6 |
| Utah | 41 | 96 | 98 | 134 | 2 |
This table shows data on confirmed COVID-19 deaths for 4 European locations and 11 U.S. locations where seroprevalence has been assessed [27, 124, 129, 163–165]. Sources of fatality data are given in Supplementary Appendix F. For each location, the second column shows cumulative fatalities from the onset of the pandemic until the midpoint date of that seroprevalence study, while the next two columns report cumulative deaths 4 and 5 weeks later, respectively. The last two columns show the percent change in cumulative fatalities over each specified time interval (weeks 0–4 and weeks 4–5, respectively)